Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Valion Bio (TIVC) Shares Outstanding (Diluted Average) (2021 - 2025)

Valion Bio has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $739618.0 for Q2 2025.

  • For Q2 2025, Shares Outstanding (Diluted Average) rose 359.1% year-over-year to $739618.0; the TTM value through Jun 2025 reached $739618.0, up 359.1%, while the annual FY2024 figure was $287370.0, 516.01% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q2 2025 was $739618.0 at Valion Bio, up from $596368.0 in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $9.7 million in Q1 2022 and troughed at $46650.0 in Q4 2023.
  • A 5-year average of $2.1 million and a median of $581298.0 in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): plummeted 97.93% in 2023 and later surged 590.74% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $3.5 million in 2021, then plummeted by 97.23% to $96778.0 in 2022, then crashed by 51.8% to $46650.0 in 2023, then surged by 516.01% to $287370.0 in 2024, then skyrocketed by 157.37% to $739618.0 in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for TIVC at $739618.0 in Q2 2025, $596368.0 in Q1 2025, and $287370.0 in Q4 2024.